Introduction {#sec1}
============

Groundbreaking results from the Human Genome Project revealed extensive complexity in our DNA sequence and unleashed new opportunities in biomedical and clinical trial studies ([@ref27]; [@ref18]). Correspondingly, this nucleotide complexity aligns with the multifactorial etiology of many human diseases. Clinical trials that traditionally target single proteins or nodes in biological pathways often fail to reverse pathogenic phenotypes ([@ref25]; [@ref16]; [@ref35]), further compelling new therapeutic options. As the completion and publication date of the Human Genome Project nears the 20-year mark, the landscape of biomedicine continues to evolve, and likely will for decades to come as massive amounts of sequence data are computationally analyzed and investigated.

Future clinical trials will likely continue to capitalize on the revolutionary findings from the Human Genome Project that RNA transcripts far outnumber protein-encoding genes. This is a significant paradigm shift from the decades-old "central dogma" that one RNA makes one protein. Further, the classes of these nonprotein-coding RNAs (ncRNAs) have vastly expanded with ongoing research studies and now include transcripts such as microRNAs (miRNAs), natural antisense transcripts, Piwi-interacting RNA (piRNAs), and long ncRNAs (lncRNAs) ([@ref1]; [@ref50]; [@ref42]). Arguably, miRNAs are one of the most predominantly represented ncRNA groups in clinical research. A typical miRNA is processed from a long primary RNA sequence to a short mature functional transcript around 22 nucleotides in length. A common characteristic of an miRNA is its ability to pleiotropically target potentially hundreds or even thousands of genes, and some function in an organ- or cell-specific manner ([@ref1]). Correspondingly, this opens up the possibility of one miRNA candidate having the capability to regulate entire biological pathways that are pathogenically disrupted in a patient. Indeed, miRNAs are proving to be therapeutically advantageous, particularly in health conditions or diseases that may not be provoked by a single genetic link. Although the pleiotropic nature of miRNAs undeniably makes off-target biological effects a concern, similar nonspecific responses have also occurred with traditional therapeutics that target single protein-coding genes. Collectively, small molecule drugs have successfully been pharmacologically designed to pleiotropically target multiple targets or pathways ([@ref16]; [@ref31]), providing further support to miRNAs as future therapeutics.

Preclinical Validation of miRNA Therapeutics {#sec2}
============================================

Bioinformatic Analysis {#sec3}
----------------------

Certain mechanistic functions of candidate miRNAs can be assessed bioinformatically and/or *in vitro* prior to testing in preclinical animal models. A growing number of databases are available to predict miRNA regulatory targets ([@ref1]; [@ref50]). Ideally, multiple independent algorithms are used cooperatively for successful prediction of miRNA-binding sites in protein-coding genes and their associated biological networks. One of the first and most consistently published algorithms, TargetScan, came from the laboratory of David Bartel. TargetScan predicts miRNA gene targets based on seed regions that are critical for binding to mRNA, which includes almost all identified miRNA sequences reported in miRBase to date. Moreover, established bioinformatic platforms such as Kegg and IPA/Ingenuity identify putative biological pathways, and in some cases disease states, targeted by miRNAs. There are also computational programs to calculate the free energy between two select RNA sequences of interest, with a lower free energy (typically around −20 or less) suggestive of more stringent binding ([@ref29]; [@ref40]). Websites such as <https://tools4mirs.org/> provide links to a majority of the currently available software. Future streamlining of clinical research data repositories with miRNA bioinformatic platforms could further facilitate identification and evaluation of therapeutic candidates.

*In vitro* and *in vivo* Validation {#sec4}
-----------------------------------

A variety of cell culture platforms are now available to assess the mechanisms, toxicity, and potential therapeutic efficacy of miRNA candidates *in vitro*. Primary cells, immortalized cell lines, and induced-pluripotent stem (IPS) cells are readily available for epigenetic manipulation of target transcripts. IPS cells allow for modulation and monitoring of biological pathways along distinct stem cell lineages from a skin tissue source ([@ref21]; [@ref44]). Indeed, vectors and modified oligonucleotides to either overexpress or silence miRNA function are generated for many of these ncRNAs and accessible to biomedical research laboratories. High-throughput capacities to screen and validate bioinformatic predictions *in vitro* have significantly facilitated and expedited preclinical study of putative therapeutic transcripts. Further, with the extensive collection of animal models available commercially or through academic laboratories, *in vivo* validation is increasingly feasible and rapid. Nonhuman primate models have also been successfully incorporated into preclinical miRNA investigations and supported the initiation of clinical trials, such as for the miR-122 repressor, Miravirsen, in the treatment of Hepatitis C Virus (HCV) ([@ref28]; [@ref19]).

miRNAs as Biomarkers in Clinical Medicine {#sec5}
=========================================

A growing number of reports have shown that subsets of miRNAs may have clinical relevance as biomarkers. These biomarkers can be used to indicate presence of a pathology and even the stage, progression, or genetic link of pathogenesis ([@ref24]; [@ref48], [@ref49]; [@ref52]; [@ref10]; [@ref30]; [@ref38]; [@ref41]; [@ref4]; [@ref17]). In certain situations, one miRNA biomarker may be sufficient to identify a health outcome; however, in other cases, a well-defined panel of miRNAs is necessary for increased diagnostic sensitivity and/or specificity. These investigations have been undertaken in preclinical animal models and in populations of humans. For example, studies in a subset of patients with frontotemporal dementia showed distinctive miRNA expression patterns between patients with or without mutations in the gene for progranulin. Further, these distinctive miRNA profiles in some cases were brain region specific to sites of pathology ([@ref24]). In this era of rapid access to cutting-edge genome (DNA), transcriptome (RNA), and proteome (protein) data and technology, the continued merging of biomarkers in patient care will undoubtedly enable earlier diagnosis and expedited medical intervention decisions. It is possible that a subset of miRNA biomarkers may also function as viable drug candidates.

To date, a number of registered clinical studies in the [clinicaltrials.gov](http://clinicaltrials.gov) database for miRNA biomarkers have been completed; this includes phase 4 trials that monitored select miRNAs as biomarkers for disease progression in patients receiving FDA-approved drugs. Trials have assessed or are actively recruiting patients to examine the profiles of these ncRNA transcripts in a range of health conditions such as diabetes, coronary heart disease, breast cancer, lupus, epilepsy, depressive disorder, stroke, Addison's disease, influenza, liver disease, and even toxic exposure to agents such as acetaminophen. Additionally, as miRNAs are ubiquitously expressed throughout the body, they can readily be measured from peripheral blood, tissue biopsies, saliva, urine, cerebrospinal fluid (CSF), and other biological samples ([@ref51]; [@ref11]; [@ref43]). Notably, as miRNAs are able to cross the blood-brain barrier, they can potentially be quantitated in routine blood, serum, or plasma tests as measures for various neurodegenerative and neurodevelopmental impairments. Indeed, these miRNA diagnostic blood tests to assess brain health are a primary focus of the biotech company DiamiR.

The source of the miRNA candidate influences how accessible it is as a biomarker, how the miRNA is extracted from the biological specimen, and even how it is analyzed. In fluid specimens such as blood, the miRNA content can originate through a few pathways, including extracellular vesicles (exosomes) ([@ref20]; [@ref3]; [@ref37]; [@ref36]). Ongoing investigations continue to probe whether enrichment of exosomes from biological samples or more crude cell-free preparations are more reliable in biomarker measurements; and some reports suggest it may depend on the specific human disease. Vesicle purification can lower the RNA yield and integrity. Correspondingly, because of lower RNA concentration, this can lead to more interindividual variability. Further, a disease-specific alteration in exosome release and clearance, or administration of therapeutics that alter blood volume, can also skew RNA yield ([@ref5]). Thus, taking into account disease state and medical treatments may improve biomarker analyses. In addition to cell secretory mechanisms, circulatory RNAs are also derived from cell death, tumor necrosis, or even lipoprotein-mediated transport ([@ref22]). Levels of miRNAs from biological fluids are routinely quantitated in academic, industry, and hospital laboratory settings by Next-Generation Sequencing, real-time PCR, or microarray platforms and data subsequently normalized to appropriate small RNA controls.

Clinical Research Studies of miRNAs as Medical Intervention Drugs {#sec6}
=================================================================

This is an exciting time for therapeutic small RNA (less than 200 nucleotides in length) drugs, as the first small-interfering RNA (siRNA) was recently granted FDA approval in 2018. The siRNA drug, Patisiran, is approved for a rare polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis and works by binding and degrading the messenger RNA transcript for transthyretin ([@ref26]; [@ref54]). Although the emergence of miRNA therapeutics has not yet translated into FDA-approved candidates for medical intervention, candidate drugs are in clinical development or in phase 1 and phase 2 clinical trials. Academic laboratories, biotech companies, and the pharmaceutical industry are all involved in the clinical research efforts. There are biotech companies focused exclusively on advancing miRNA-related drug pipelines, such as Miragen, MiRNA Therapeutics (now Synlogic), and Regulus Therapeutics.

To date, there is reported clinical utility in peripheral tissues for miRNA mimics (to overexpress the transcript) as well as miRNA repressors (to silence the transcript function). Systemic delivery methods of miRNA drugs parallel those of traditional therapeutics with injection or intravenous administration. For cancer-related pathologies, intratumoral injections of miRNA drugs directly into the pathogenic site can enhance target specificity, efficacy, and minimize side effects ([@ref32]; [@ref6]). Arguably, one big hurdle is delivery of drugs to the brain, which has been an ongoing area of investigation for decades even prior to the Human Genome Project publication. Modified micelle, liposome, nanoparticle, intranasal, and other delivery methods have all been tested for blood-brain barrier crossing and delivery with varying levels of success ([@ref12]; [@ref9]). Although cerebrospinal fluid administration is an option, it has its own efficacy issues and is an invasive procedure with significant risks. Complicating design for delivery of drugs to the brain is that only lipid-soluble small molecules less than 400 daltons are able to cross the blood-brain barrier, macromolecules cannot successfully penetrate.

Putative miRNA drugs have exhibited significant efficacy in a range of health conditions, including cancer, hepatitis C, heart abnormalities, kidney disease, pathologic fibrosis, and even keloid formation. In line with other clinical trials, some miRNA candidates have shown potential, while some have failed and the study was terminated. For example, in 2016, the biotech company MiRNA Therapeutics (now Synlogic) halted phase 1 trials of its miRNA-34 drug mimic, MRX34, for use in cancer after severe adverse events (SAE) were reported in five patients experiencing serious immune responses. Due to the development of SAE, future phase 2 trials of MRX34 for melanoma were also terminated.

Although no miRNA drug candidates have been entered into [clinicaltrials.gov](http://clinicaltrials.gov) database for phase 3 trials to date, there are active earlier phase trials to investigate new miRNA drug candidates in addition to the previously mentioned miR-122/Miravirsen studies. There is ongoing recruitment of patients for a phase 1 trial of the drug MRG 110, a locked nucleic acid (LNA)-modified antisense oligonucleotide to inhibit the function of miR-92. The company miRagen recently announced a second phase 1 trial with MRG 110 with a future potential clinical application toward wound healing as well as heart failure. Miragen also has an active phase 1 study for miR-29 (MRG-201) to treat keloid and scar tissue formation as well as a phase 2 trial for miR-155 (Cobomarsen; MRG-106) for patients with a form of T-cell lymphoma. This year (2019), Regulus announced their new miRNA drug candidate nominee RGLS5579 that targets miR-10b for potential trials in patients diagnosed with glioblastoma multiforme, one of the most aggressive forms of brain cancer with a median survival of approximately 14.6 months ([@ref13]). After recent restructuring of Regulus, Sanofi will assume costs for phase 2 trials of Regulus drug candidate RG-012 to silence miR-21 function in patients with Alport syndrome.

The first recently completed phase 1 trial engaging a newer technology termed a "TargomiR" exhibited encouraging results in patients with recurrent malignant pleural mesothelioma or non-small cell lung cancer. In brief, TargomiR delivery vehicles contain an miRNA mimic, bacterially derived minicells, and a targeting moiety (i.e., a specific antibody that recognizes a protein on target cells). In the first human trial of a TargomiR drug, MesomiR-1, the miRNA mimic was the reported tumor suppressing transcript miR-16 and the targeting moiety was an antibody to the epidermal growth factor receptor (EGFR) that is consistently deregulated in lung cancer cells ([@ref39]; [@ref46]). These studies provide new hope to mesothelioma patients in which less than 10% survive more than 5 years ([@ref8]). Overall, these studies and reports suggest a viable future for miRNA drugs in diseases with no current effective treatments ([Table 1](#tab1){ref-type="table"}).

###### 

Interventional clinical trials for miRNAs.

  miRNA gene; drug name                           Clinical trial number; phase status                  Disease/disorder investigated
  ----------------------------------------------- ---------------------------------------------------- ---------------------------------------
  miR-34; MRX34                                   NCT01829971; phase 1 (terminated)                    Liver cancer, lymphoma
  NCT02862145; phase 1 (withdrawn)                melanoma                                             
  miR-92; MRG 110                                 NCT03603431; phase 1 (recruiting)                    wound healing, heart failure
  miR-16; MesomiR-1                               NCT02369198; phase 1 (completed)                     Mesothelioma, lung cancer
  miR-122; Miravirsen                             NCT02508090; phase 2 (completed)                     Hepatitis C virus
  NCT02452814; phase 2 (completed)                                                                     
  NCT01200420; phase 2 (completed)                                                                     
  NCT01872936; phase 2 (unknown status)                                                                
  NCT01727934; phase 2 (unknown status)                                                                
  NCT01646489; phase 1 (completed)                                                                     
  miR-29; MRG-201                                 NCT03601052; phase 1 (recruiting)                    Keloid, fibrous scar tissue formation
  miR-21; RG-012                                  NCT02855268; phase 2 (suspended, sponsor decision)   Alport syndrome
  NCT03373786; phase 1 (active, not recruiting)                                                        
  miR-155; Cobomarsen (MRG-106)                   NCT03713320/phase 2 (recruiting)                     T-cell lymphoma/mycosis fungoides
  NCT03837457/phase 2 (new/not yet recruiting)                                                         

Drug Resistance and miRNAs {#sec7}
==========================

A problem that continues to plague current treatment options in clinical medicine is drug resistance, including life-saving chemotherapeutics in patients with cancer. A number of published reports show that manipulating expression of specific miRNAs can alter the drug sensitivity or that miRNAs are themselves biologically involved in the body's resistance response. Many of the standard therapies for breast cancer, such as Doxorubicin, Cisplatin, and Taxol, are all associated with deregulated miRNAs which may modulate resistance to the drug ([@ref17]). Evidence suggests select miRNAs may even participate in treatments to breast cancer tumors that are specifically linked to high levels of estrogen receptors.

The role of miRNA transcripts in drug resistance is reportedly not restricted to cancer pathologies. The expression of miRNAs is associated with drug resistance in treatment of conditions such as epilepsy ([@ref49]), multidrug-resistant (MDR) tuberculosis ([@ref47]), and insulin sensitivity ([@ref15]; [@ref33]). Notably, insulin sensitivity may not only impact the medical care of a diabetic patient, but studies also indicate its association with the onset of Alzheimer's disease (AD) or other dementias. In fact, Mayo Clinic estimates approximately 80% of AD patients have Type 2 diabetes or insulin resistance ([@ref23]).

Specific mechanisms of drug resistance mediated by miRNAs are under ongoing investigation. Accumulating evidence, however, shows that the ATP-binding cassette (ABC) transporter family of proteins that activate drug resistance are regulated by miRNAs ([@ref14]; [@ref53]). The ABC family includes P-glycoprotein (Pgp), multidrug resistance-associated proteins (MRP), and breast cancer resistance proteins (BCRP), all of which can pump out drugs to create additional biological energy through ATP hydrolysis ([@ref7]; [@ref36]). A recent report suggests miR-298 binds to the Pgp gene, thereby silencing the expression of Pgp and its ability to pump out antiepileptic drugs ([@ref53]). In another recent study, restoration of miR-495 levels in non-small lung cancer cells reversed cisplatin resistance through a signaling pathway that represses levels of the ABCG2 protein ([@ref14]). It is possible that co-administration of standard chemotherapeutics along with a select miRNA drug may help limit drug resistance in some cases through silencing of key proteins that directly promote low drug bioavailability or through alternate signaling pathways such as miR-155 in lung cancers ([@ref45]; [@ref2]).

Conclusion {#sec8}
==========

As the pioneering discoveries from the Human Genome Project shift the landscape of clinical research, emerging miRNA therapeutics are offering new promise in health conditions that remain elusive to current treatment options. Development of bioinformatic programs for identification of miRNA-binding sites in target genes and their corresponding implicated biological pathways, along with an expanding platform of *in vitro* and *in vivo* preclinical research models, has helped expedite the translation of miRNAs into clinical medicine. The first siRNA human trial was conducted in 2004 and in 2018 the first siRNA drug was approved ([@ref34]), paving the way for the miRNA class of transcripts that began to be actively investigated in basic biomedical research laboratories approximately 15 years ago. Indeed, as we now know the number of ncRNA transcripts is significantly greater than protein-coding genes, future human trials will undoubtedly expand their focus on epigenetic targets.
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